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recent developments in our understanding of the cellular 
regulation of APP   -secretase cleavage. Moreover, it high-
lights the particular importance of endocytic APP trafficking 
as a prime modulator of APP shedding. 
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 Proteolytic Processing of APP 
 The amyloid precursor protein (APP) is one of a large 
number of membrane proteins that are proteolytically 
converted to their soluble counterparts. This process is 
referred to as ectodomain shedding and is an important 
way of regulating the biological activity of membrane 
proteins [reviewed in  1, 2 ]. The shedding of APP may oc-
cur through two different protease activities termed   - 
and   -secretase, which cleave APP within its ectodomain 
close to its transmembrane domain [for a review, see  3 ]. 
APP cleavage by   - or   -secretase is a key regulatory pro-
cess in the generation of the amyloid-  (A  ) peptide, 
which is assumed to play an essential role in the patho-
genesis of Alzheimer’s disease (AD).   -Secretase, which 
is the aspartyl protease BACE1, cleaves APP at the N-ter-
minus of the A  peptide domain and thus catalyzes the 
first step in A  peptide generation  [4] . Subsequently, the 
 Key Words 
 Amyloid precursor protein   Alzheimer’s disease   
Ectodomain shedding   Secretases   Endocytosis   
Endophilin  
 Abstract 
 Proteolytic cleavage in the ectodomain of the amyloid pre-
cursor protein (APP) is a key regulatory step in the genera-
tion of the Alzheimer’s disease amyloid-  (A  ) peptide  and 
occurs through two different protease activities termed   - 
and   -secretase. Both proteases compete for APP cleavage, 
but have opposite effects on A  generation. At present, little 
is known about the cellular pathways that control APP   - or 
  -secretase cleavage and thus A  generation. To explore the 
contributory pathways in more detail we have recently em-
ployed an expression cloning screen and identified several 
activators of APP cleavage by   - or   -secretase. Among them 
were known activators of APP cleavage, for example protein 
kinase A, and novel activators, such as endophilin and the 
APP homolog amyloid precursor-like protein 1 (APLP1). 
Mechanistic analysis revealed that both endophilin and 
APLP1 reduce the rate of APP endocytosis and strongly in-
crease APP cleavage by   -secretase. This review summarizes 
the results of the expression cloning screen in the context of 
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remaining C-terminal APP fragment is cleaved by   -
secretase within its transmembrane domain at the C-ter-
minus of the A  domain, leading to the secretion of the 
A  peptide  [5] . In contrast to   -secretase,   -secretase 
cleaves within the A  sequence, and thereby precludes 
the generation of the A  peptide.   -Secretase is a member 
of the ADAM ( a  d isintegrin  a nd  m etalloprotease) family 
of proteases [for a review, see  6 ].   - and   -secretase com-
pete for the ectodomain cleavage of APP  [7] ( fig. 1 ), but 
have opposite effects on A  generation. Additionally, 
  - but not   -secretase generates a secreted form of APP 
(APPs  ), which has neurotrophic and neuroprotective 
properties [reviewed in  8 ]. Thus, shifting APP shedding 
away from   - towards   -secretase cleavage may be thera-
peutically beneficial for AD. In order to do so, it is essen-
tial to understand the cellular pathways that regulate the 
activity of both proteases. At present, little is known 
about the cellular regulation of BACE1. In contrast, APP 
  -secretase cleavage can be regulated in the cell through 
different mechanisms, which can be broadly grouped 
into three categories. First, an activation of distinct intra-
cellular signaling mechanisms or a change in the mem-
brane composition increases APP   -shedding [for re-
views, see  6, 8 ]. Second, changes in APP endocytosis alter 
  - and   -secretase cleavage, because   -secretase cleavage 
occurs at or very close to the plasma membrane  [9] , 
whereas   -secretase cleavage of APP mainly occurs after 
endocytosis in the endosomes. Third, the interaction of 
APP with cytoplasmic adaptor proteins alters APP shed-
ding [for a review, see  10 ], presumably by affecting APP 
trafficking and access of APP to the secretases. For all 
three categories the molecular mechanisms underlying 
the increase in APP shedding are only partly understood. 
Thus, we have recently employed expression cloning to 
explore the contributory cellular pathways systematically 
and obtained several proteins activating APP shedding 
 [11, 12] . The identified proteins fall into the three general 
categories of APP shedding activators described above. 
This review summarizes their mechanistic analysis in the 
context of recent developments in our understanding of 
the cellular regulation of APP   -cleavage. This highlights 
the particular importance of the endocytic trafficking of 
APP as a prime modulator of APP shedding.
 Expression Cloning Screen for Modifiers of APP 
Shedding 
 For the expression cloning screen, a reporter cell line 
was used that allows measurement of APP shedding in a 
high-throughput format. For this aim, human embryon-
ic kidney 293 cells were used that stably express a fusion 
protein consisting of alkaline phosphatase fused to the 
N-terminus of full-length APP  [12] . The 293 cells are a 
well-established cellular model for the analysis of APP 
shedding and have the additional advantage that they can 
be transfected with very high efficiency, which was an es-
sential requirement for the screening approach used. In a 
‘sib-selection’ or ‘pool-subdivision’ approach, we first 
used pools of 96 cDNAs from a human brain cDNA li-
brary and screened them for activators of APP shedding 
( fig. 2 ). Next, to identify the individual cDNA within the 
pool, which was responsible for activation of APP shed-
ding, the pooled cDNAs were further subdivided and in-
dividual cDNAs from that pool were tested for their APP 
shedding-enhancing activity. With this approach, eight 
cDNAs were obtained that stimulate the shedding of APP 
( table 1 ). They encode protein kinase A (PKA), an N-ter-
minally truncated form of the kinase MEKK2, metabo-
tropic glutamate receptor 3 (mGluR3), endophilins A1 
and A3, numblike, an N-terminally truncated form of 
the palmitoyl-protein thioesterase 1 and the APP homo-
log amyloid precursor-like protein 1 (APLP1)  [11, 12] . 
 cDNAs inhibiting APP secretion were not obtained. Al-
together, around 100,000 cDNAs were screened. Consid-
ering that cDNA libraries contain many partial cDNAs 
 Fig. 1. Ectodomain shedding of APP shedding by   - and   -secre-
tase.   -Secretase cleavage of wild-type APP occurs at or very close 
to the cell surface, whereas   -secretase cleavage mainly takes 




and that cDNAs expressed at high levels are overrepre-
sented in the library, we assume that many more cDNA 
clones would need to be screened to cover all distinct 
cDNAs found in the library. The identification of PKA is 
in agreement with previous publications showing that an 
activation of PKA by forskolin in rat pheochromocytoma 
PC12 cells  [13] and in human embryonic kidney 293 cells 
 [14] increased APP shedding. This validates the screen-
ing approach as it shows that physiologically relevant 
 cDNAs can be obtained.
 Specificity of Identified cDNAs for APP Shedding 
 Some of the identified cDNAs, such as the endophilins 
and mGluR3, activated APP shedding in a relatively spe-
cific manner, as they had essentially no effect on the shed-
ding of unrelated membrane proteins, such as TNF 
 receptor 2 (TNFR2), P-selectin glycoprotein ligand-1 
(PSGL-1) or L-selectin  [12] . Like APP, all three proteins 
are subject to ectodomain shedding by ADAM proteases. 
APLP1 strongly activated shedding of APP but not of
L-selectin ( fig. 3 ), demonstrating that APLP1 does not 
stimulate the shedding of all ADAM protease substrates. 
Other proteins, such as PKA and the kinase MEKK2, 
 activated the shedding of L-selectin ( fig. 3 , shown for 
MEKK2) or of TNFR2  [12] much more strongly than the 
shedding of APP, showing that they are not specific acti-
vators of APP shedding, but instead may contribute to a 














 Fig. 2. Expression cloning screen for mod-
ulators of APP shedding. The reporter cell 
line consists of human embryonic kidney 
293 cells, which stably express a fusion 
protein of alkaline phosphatase (AP) and 
full-length APP. Cleavage of APP by   - or 
  -secretase leads to the secretion of the fu-
sion protein into the conditioned medium, 
where it can be detected and quantified by 
measuring the alkaline phosphatase re-
porter enzyme activity. Cells were plated 
into 96-well plates and transfected with 
pools of cDNAs. APP fusion protein secre-
tion was measured in all wells. In wells 
with altered APP secretion, the corre-
sponding cDNA was identified and mech-
anistically characterized. 
Table 1. Activators of APP shedding obtained by expression cloning
Protein encoded by cDNA Full-length or partial cDNA
Protein kinase A, catalytic -subunit full-length






Palmitoyl-protein thioesterase 1 lacking the 5 end of the coding sequence; encoding an
N-terminally truncated protein
APLP1 full-length
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 Cellular Control of APP Ectodomain Shedding by 
Signal Transduction Cascades 
 The APP shedding activators PKA and MEKK2 are 
part of signal transduction pathways, which have previ-
ously been shown to control the amount of APP shed-
ding. The   -secretase cleavage of APP can be stimulated 
by MAP kinase signaling, insulin signaling and signaling 
through PKA or specific G protein-coupled receptors [for 
reviews see  6, 8 ] as well as by calcium  [15] . For example, 
growth factors, such as EGF, or the phorbol ester PMA 
can activate the MAP kinase cascade and stimulate APP 
shedding. The molecular and cellular processes activated 
by these cascades and the mechanisms by which they fi-
nally mediate the increase in APP shedding remain large-
ly unknown. Additionally, a diverse group of compounds, 
such as cholesterol, steroid hormones, nonsteroidal anti-
inflammatory drugs and cholinesterase inhibitors can 
modulate APP   -secretase cleavage. The underlying mo-
lecular mechanisms are partly understood and have been 
described in more detail elsewhere [for a review, see  6 ].
 One of the proteins identified in the screen, mGluR3, 
is a novel activator of APP shedding and belongs to the 
eight-member family of mGluRs. mGluR3 may be par-
ticularly interesting for studying APP shedding, as it was 
one of the cDNAs showing a specific effect on the shed-
ding of APP. Two members of the mGluR family, mGluR1 
and mGluR5, have previously been shown to stimulate the 
secretion of APP  [16] . Both mGluRs activate phospholi-
pase D. In contrast, the identified mGluR3 negatively reg-
ulates adenylate cyclase and thus, points to a possible role 
of this separate pathway in the control of APP shedding.
 Control of APP Shedding by Modulators of General 
Endocytosis 
 A strong activator of APP shedding identified in the 
screen was endophilin A3, which belongs to the en-
dophilin family of endocytic and signal transducing pro-
teins  [17] . Endophilin consists of a Bin/amphiphysin/Rvs 
domain, which may be involved in protein dimerization 
and sensing of membrane curvature, and of a SH3 do-
main. Endophilin A3 increased APP shedding even 
stronger than the metalloprotease ADAM10  [11, 12] , 
which is one of the candidate   -secretases for APP. Im-
portantly, we found that endophilin A3 specifically in-
creased APP   -secretase cleavage and had no significant 
effect on   -secretase cleavage. Mechanistically, en-
dophilin A3 inhibits the rate of APP endocytosis, as mea-
sured in a validated anti-APP antibody uptake assay us-
ing COS cells cotransfected with APP and either en-
dophilin A3 or GFP as a control  [11, 12] . As a result, more 
APP becomes available at the cell surface for an increased 
  -secretase cleavage. This fits with previous studies 
showing that a mutant form of APP, which lacks its cyto-
plasmic domain including its internalization motif, shows 
a strong reduction in endocytosis resulting in more APP 
at the cell surface and increased APP shedding  [18] . A 
strong increase in APP shedding, mainly mediated by
  -secretase, was also observed for a dominant-negative 
mutant of the endocytic GTPase dynamin, which inhibits 
endocytosis of many membrane proteins, including APP 
 [19, 20] . Conversely, expression of the small G protein 
Rab5 in murine L1 cells enhances APP endocytosis, re-
sulting in an increased APP cleavage by   -secretase, in 
increased A  generation and in abnormally enlarged en-







































 Fig. 3. Specificity of the stimulatory effect of APLP1 on the shed-
ding of APP. Kidney 293 cells stably expressing alkaline phospha-
tase fusion proteins of APP or L-selectin were transiently trans-
fected with control vector (Con), APLP1 or MEKK2. AP activity 
was measured in the conditioned medium and represents the 
mean and standard deviation of two to three independent exper-
iments, each one carried out in duplicate. Alkaline phosphatase 
activity was normalized to the protein concentration in the cell 
lysate. The data for APP were part of the set of experiments shown 




 Expression of endophilin A3 not only inhibited the 
endocytosis of APP but also the endocytosis of fluores-
cently labeled transferrin  [12] , revealing that endophilin 
A3 is a general, negative regulator of endocytosis, poten-
tially similar to mutants of the endocytic GTPase dyna-
min. Despite its more general role in endocytosis, the en-
dophilin A3 had a strong effect only on APP shedding but 
no or only a minor effect on the shedding of other mem-
brane proteins, such as TNFR2 or PSGL-1  [12] . This sug-
gests that APP stands out among other shedding sub-
strates in that its shedding is particularly sensitive to 
changes in the rate of endocytosis. At present, it is unclear 
why this is so. Potentially, the endocytosis of TNFR2 and 
PSGL-1 is regulated differently than the endocytosis of 
APP or may have a different time course.
 APP Interactors Influence APP Shedding 
 APP is at the center of a complex protein-protein in-
teraction network involving cytoplasmic adaptor and 
transmembrane proteins, but the functional role of these 
interactions is only partly understood. Most of the cy-
toplasmic interactors seem to compete for the same 
binding site at or around the conserved GYENPTY mo-
tif in the cytoplasmic tail of APP [for recent reviews on 
APP interactors, see  10, 22 ]. For example, FE65, X11, and 
JIP have been shown to bind to this motif and to alter 
APP shedding, revealing that a change in the interaction 
of APP with its binding partners is a way to modulate 
APP shedding. FE65 and X11 have been best studied 
among the interactors and have opposite effects on APP 
cleavage. X11 decreases APP shedding, presumably by 
retaining APP in early compartments of the secretory 
pathway. In contrast, FE65 stimulates APP shedding. A 
specific mechanism of how FE65 controls the shedding 
of APP, but not of unrelated membrane proteins, has 
been put forward by us and several other groups using 
different experimental approaches  [11, 23–27] . Accord-
ing to this model, FE65 links APP to the LDL receptor-
related protein (LRP;  fig. 4 A), which is a multifunction-
al cell surface receptor for proteins involved in lipopro-
tein metabolism  [28] . Formation of the APP-FE65-LRP 
complex allows efficient endocytosis of APP ( fig. 4 A). In 
contrast, disruption of the complex leads to a reduction 
in APP endocytosis, resulting in an accumulation of 
APP at the cell surface, where it undergoes increased 
  -secretase cleavage and reduced   -secretase cleavage 
( fig. 4 B). This is the case in LRP-deficient cells or upon 
RNAi-mediated knockdown of FE65  [23, 24, 29] . Like-
wise, overexpression of FE65 results in the disruption of 
the complex, presumably by leading to APP-FE65 com-
plexes and to separate FE65-LRP complexes. Both kinds 
of complexes lack the third binding partner and there-
fore are not functional with regard to APP endocyto-
sis.
 APLP1 Modulates APP Shedding 
 An essential validation of the model described above 
came from work that we carried out in collaboration with 
Claus Pietrzik and Christian Haass  [11] . We found that 
the APP-FE65-LRP complex can also be disrupted when 
proteins are expressed that can functionally replace APP 
in terms of complex formation with FE65 and LRP, leav-
ing APP without its binding partners ( fig. 4 C). This hap-
pens when the two homologs of APP, APLP1 and APLP2, 
are expressed. A detailed mechanistic analysis revealed 
that APLP1 expression reduces APP endocytosis, strong-
ly increases APP   -secretase cleavage and reduces APP 







APP LRP APP APLP1
 Fig. 4. Model for the APP-FE65-LRP complex.  A In LRP express-
ing wild-type cells APP, FE65 and LRP form a complex, allowing 
efficient APP endocytosis (bold vertical arrow) and resulting in 
low levels of APP shedding (thin horizontal arrow). Size of pro-
teins is not drawn to scale.  B In LRP-deficient cells (LRP–/–), en-
docytosis of APP is reduced and APP shedding is increased (bold 
horizontal arrow).  C In cells transfected with APLP1, LRP prefer-
entially forms a complex with APLP1, resulting in APP not being 
complexed to LRP. This results in a state resembling LRP defi-
ciency ( B ) and an increase in APP shedding (bold horizontal ar-
row). M = Membrane. Figure adapted from Neumann et al.  [11] . 
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APP shedding is only observed in LRP-expressing cells, 
but not in LRP knock-out cells, showing that this effect is 
LRP dependent. Additionally, mutational analysis re-
vealed that the FE65-binding motif in APLP1 needs to be 
present in order to increase APP shedding. Importantly, 
proteins that do not bind FE65 did not affect APP shed-
ding, consistent with the APP-FE65-LRP complex being 
required for APP endocytosis and shedding. Together, 
these experiments raise the possibility that changes in the 
expression levels of the APP homologs APLP1 and APLP2 
may influence the shedding of APP. In fact, expression 
levels of APLP1, APLP2 and even of APP are differen-
tially regulated upon physiological and pathophysiologi-
cal stimuli, such as during embryonic development, neu-
ronal migration and wound repair  [30, 31] . These stimu-
li may in turn alter the amount of APP shedding. Future 
studies need to show, whether the complex only consists 
of the three proteins APP-FE65-LRP, or whether it is part 
of a multi-protein complex. Given that FE65 consists of 
several protein-protein interaction domains, it is likely 
that FE65 may link the complex to other proteins. In fact, 
FE65 colocalizes with APP in actin-rich lamellipodia in 
neuronal growth cones  [32] and may link APP to cellular 
motility  [33] .
 Modulation of APP Shedding by the Transmembrane 
Proteins LRP1B and BRI2 
 Interestingly, a homolog of LRP, LRP1B, may form a 
similar complex with APP as LRP itself. A recent study 
showed that LRP1B can also be coimmunoprecipitated 
with APP  [34] . It remains to be established whether this 
interaction is also mediated by FE65. In contrast to LRP, 
which is rapidly endocytosed and mediates efficient APP 
endocytosis, LRP1B is very slowly endocytosed. LRP1B 
reduced APP endocytosis and again increased APP shed-
ding by   -secretase  [34] . Presumably, LRP1B forms a 
complex with APP at the expense of LRP, similar to 
APLP1, which forms the complex with LRP at the ex-
pense of APP. These experiments reinforce the notion 
that changes in the rate of APP endocytosis determine the 
amount of APP   -secretase cleavage.
 Besides LRP and LRP1B, two novel transmembrane 
interactors of APP have recently been described. Sorting 
protein-related receptor (SorLa) is a type I transmem-
brane protein of unknown function, which is expressed 
in neurons and was shown to coimmunoprecipitate with 
APP  [35] . The other protein is BRI2, which is the first 
type II membrane protein shown to coimmunoprecipi-
tate with APP  [36, 37] . Again, the function of BRI2 is un-
known, but mutant forms of BRI2 have been linked to 
dementia and cerebellar ataxia in Danish and British kin-
dreds. The name BRI seems to be derived from the British 
origin  [38] . Currently, it is unclear, whether the interac-
tion between APP and both novel proteins, SorLA and 
BRI2, occurs directly or is mediated by adapter proteins, 
as it is the case for LRP. Interestingly, expression of both 
SorLa and BRI2 strongly inhibited APP   -secretase cleav-
age and also A  generation. Although the underlying 
mechanisms remain to be established in detail, both pro-
teins seem to retain APP in early cellular compartments 
of the secretory pathway, where APP cannot reach the 
secretases.
 A surprising additional membrane protein interactor 
has recently been suggested: APP itself. Soba et al.  [39] 
proposed that APP can dimerize in  cis and in  trans at the 
cell surface. It will be interesting to see in future studies, 
whether the dimerization status of APP can influence 
APP shedding, potentially by modulating the formation 
or the endocytosis of the APP-FE65-LRP complex.
 Conclusion 
 Recently, we and others have described several novel 
modulators of APP trafficking and processing. Although 
we are only beginning to understand the underlying 
mechanisms, it becomes more and more clear that not 
only signaling cascades, changes in membrane composi-
tion and interaction of APP with cytoplasmic adaptors 
(discussed above in the first paragraph) but also changes 
in APP trafficking, and specifically in the rate of APP 
endocytosis, can have a major effect on APP processing 
by   - and   -secretase. APP endocytosis can be altered by 
general modulators of endocytosis, such as dynamin, en-
dophilin and Rab5, or by specifically targeting APP en-
docytosis, such as by altering the amount and the com-
position of the APP-FE65-LRP complex. Because   -secre-
tase cleavage occurs at or very close to the cell surface, 
whereas   -secretase cleavage of wild-type APP mainly 
occurs in the endosomes, a reduction in APP endocytosis 
will favor   -secretase cleavage, whereas an increase in 
APP endocytosis will enhance   -secretase cleavage and 
A  generation. Interestingly, one of the first pathological 
changes in AD brain are abnormalities in endosomal 
morphology [reviewed in  40 ]. Enlarged endosomal struc-
tures are observed long before the onset of the disease and 
are very similar to the changes seen in cultured cells with 




Together, these findings indicate that alterations in the 
rate of APP endocytosis may increase A  generation not 
only in cultured cells but also in vivo and may contribute 
to AD pathogenesis. 
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